Patents by Inventor Iyassu Sebhat
Iyassu Sebhat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240115587Abstract: This disclosure is directed, at least in part, to combination therapies comprising GPR119 agonists and GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the condition or disorder is: a metabolic disorder, such as diabetes, obesity, or nonalcoholic steatohepatitis (NASH); a nutritional disorder, such as short bowel syndrome; or an eating disorder, such as binge eating disorder.Type: ApplicationFiled: November 6, 2023Publication date: April 11, 2024Inventors: Shirly PINTO, Iyassu SEBHAT, Brett LAURING, Nancy A. THORNBERRY
-
Publication number: 20240101558Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.Type: ApplicationFiled: November 1, 2023Publication date: March 28, 2024Inventors: Iyassu SEBHAT, Shuwen HE, Ann WEBER, Nancy THORNBERRY, Lisa KRUG, Paul RICHARDS, Brett LAURING
-
Patent number: 11851429Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.Type: GrantFiled: January 26, 2022Date of Patent: December 26, 2023Assignee: KALLYOPE, INC.Inventors: Iyassu Sebhat, Shuwen He, Ann Weber, Nancy Thornberry, Lisa Krug, Paul Richards, Brett Lauring
-
Publication number: 20230151037Abstract: This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.Type: ApplicationFiled: February 28, 2021Publication date: May 18, 2023Inventors: Iyassu SEBHAT, Shuwen HE, Simon MATHIEU
-
Publication number: 20230113609Abstract: This disclosure is directed, at least in part, to SSTR5 antagonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the SSTR5 antagonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.Type: ApplicationFiled: December 2, 2020Publication date: April 13, 2023Inventors: Iyassu SEBHAT, Shuwen HE, Christopher MOYES, Simon MATHIEU, Michael LUZUNG
-
Publication number: 20230061736Abstract: This disclosure is directed, at least in part, to GPR119 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR119 agonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.Type: ApplicationFiled: July 28, 2022Publication date: March 2, 2023Inventors: Iyassu SEBHAT, Shuwen HE, Christopher MOYES
-
Publication number: 20230050965Abstract: This disclosure is directed, at least in part, to SSTR5 antagonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the SSTR5 antagonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.Type: ApplicationFiled: December 2, 2020Publication date: February 16, 2023Inventors: Iyassu SEBHAT, Shuwen HE
-
Publication number: 20230041621Abstract: This disclosure is directed, at least in part, to SSTR5 antagonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the SSTR5 antagonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.Type: ApplicationFiled: December 2, 2020Publication date: February 9, 2023Inventors: Iyassu SEBHAT, Shuwen HE
-
Patent number: 11512065Abstract: This disclosure is directed, at least in part, to GPR119 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR119 agonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.Type: GrantFiled: February 3, 2022Date of Patent: November 29, 2022Assignee: KALLYOPE, INC.Inventors: Iyassu Sebhat, Shuwen He, Christopher Moyes
-
Publication number: 20220340599Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists, super agonists, full agonists, or partial agonists.Type: ApplicationFiled: June 22, 2022Publication date: October 27, 2022Inventors: Iyassu SEBHAT, Shuwen HE
-
Publication number: 20220289772Abstract: This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.Type: ApplicationFiled: May 16, 2022Publication date: September 15, 2022Inventors: Iyassu SEBHAT, Shuwen HE
-
Patent number: 11407768Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists, super agonists, full agonists, or partial agonists.Type: GrantFiled: June 25, 2021Date of Patent: August 9, 2022Assignee: KALLYOPE, INC.Inventors: Iyassu Sebhat, Shuwen He
-
Publication number: 20220226298Abstract: This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.Type: ApplicationFiled: May 22, 2020Publication date: July 21, 2022Inventors: Iyassu SEBHAT, Shuwen HE
-
Publication number: 20220227754Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.Type: ApplicationFiled: January 26, 2022Publication date: July 21, 2022Inventors: Iyassu SEBHAT, Shuwen HE, Ann WEBER, Nancy THORNBERRY, Lisa KRUG, Paul RICHARDS, Brett LAURING
-
Publication number: 20220153719Abstract: This disclosure is directed, at least in part, to GPR119 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR119 agonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.Type: ApplicationFiled: February 3, 2022Publication date: May 19, 2022Inventors: Iyassu SEBHAT, Shuwen HE, Christopher MOYES
-
Publication number: 20220152164Abstract: This disclosure is directed, at least in part, to GPCR modulators in combination therapies useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, these modulators are gut-restricted compounds. In some embodiments, these modulators are GPCR agonists, antagonists, inverse agonists, neutral antagonists, positive allosteric modulators, or negative allosteric modulators. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes or obesity, or a nutritional disorder such as short bowel syndrome.Type: ApplicationFiled: March 19, 2020Publication date: May 19, 2022Inventors: Nancy THORNBERRY, Ann WEBER, Maja ENGELSTOFT, Zac FARINO, Ian PEIKON, Shirly PINTO, Iyassu SEBHAT, Paul RICHARDS
-
Patent number: 11279702Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.Type: GrantFiled: October 15, 2021Date of Patent: March 22, 2022Assignee: KALLYOPE, INC.Inventors: Iyassu Sebhat, Shuwen He
-
Publication number: 20220033401Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.Type: ApplicationFiled: October 15, 2021Publication date: February 3, 2022Inventors: Iyassu SEBHAT, Shuwen HE, Ann WEBER, Nancy THORNBERRY, Lisa KRUG, Paul RICHARDS, Brett LAURING
-
Publication number: 20220002317Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists, super agonists, full agonists, or partial agonists.Type: ApplicationFiled: June 25, 2021Publication date: January 6, 2022Inventors: Iyassu SEBHAT, Shuwen HE
-
Patent number: 9868733Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.Type: GrantFiled: August 19, 2013Date of Patent: January 16, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: James M. Apgar, Tesfaye Biftu, Ping Chen, Danqing Feng, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu, Ashok Arasappan